NCT04154839

Brief Summary

This is a joint research study between The Hong Kong Polytechnic University (PolyU) and The University of Hong Kong (HKU) as titled above. In view of the increasing prevalence of atopic dermatitis (AD), the lack of complete epidemiology data on childhood and adult AD in Hong Kong and the lack of complete understanding on the genetic and environmental factors associated with it, the purpose of this study to carry out an epidemiology and genetic study that targets AD patients within the local Hong Kong population. The investigators will search for new AD-associated genetic variants that are related to the local population and believe that the genetic profiles that arise from this project will form an important basis for the future management and treatment of AD, such as disease-risk screening strategy and therapeutic target development.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
450

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 12, 2019

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 29, 2019

Completed
9 days until next milestone

First Posted

Study publicly available on registry

November 7, 2019

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2022

Completed
Last Updated

May 5, 2022

Status Verified

May 1, 2022

Enrollment Period

2.5 years

First QC Date

October 29, 2019

Last Update Submit

May 4, 2022

Conditions

Keywords

Atopic dermatitisGeneticsEczemaEpidemiology

Outcome Measures

Primary Outcomes (1)

  • Significant SNPs

    The significant single nucleotide polymorphisms (SNPs) between control group and different AD case subgroups (different age of onset, different AD severity, different relapsing status), Cochran-Armitage trend test will be used to assess statistical significance of the association with each SNP, and Mantel-Haenszel method for two 2 × 2 allele frequency tables will be used to assess association of SNPs on chromosome X within male and female subjects.

    through study completion, an average of 1 year

Study Arms (2)

Atopic dermatitis group

Number of subjects in atopic dermatitis group 0 - \< 6 years : 50 subjects 6 - \<12 years : 50 subjects 12 - \<18 years : 50 subjects Adult (\>= 18 years) : 150 subjects Total no. of cases: 300 cases

Control group

\>= 40 yrs : 150 subjects

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

For AD cases: Chinese-Han AD subjects who was born in Hong Kong For Control: Chinese-Han subjects who was born in Hong Kong aged more or equal to 40 Years

You may qualify if:

  • Normal controls (Recruited in Poly U)
  • Aged more or equal to 40 \[Age of 40 is chosen as an arbitrary cutoff because studies had shown that the peak incidence among adult-onset AD cases occurs at age 20-40 years (Silvestre Salvador et al., 2017). Controls have been chosen more or equal to 40 years of age as they would likely have developed AD by the age of 40.
  • Subjects that do not have a history of AD, personal history and family history of AD including first-, second-, and third-degree relatives;
  • Subjects without a personal history and/or family history of other allergic and atopic disorders such as autoimmune diseases, skin disorders and systemic diseases.
  • Born in Hong Kong and Chinese-Han
  • AD cases (Recruited from QMH and TWH)
  • Patients have to be clinically diagnosed by a qualified dermatologist on the basis of a skin examination diagnosed according to Hanifin and Rajka criteria.
  • Children cases should be aged \< 18 at the time of recruitment and adult cases should be aged 18 at the time of recruitment;
  • Born in Hong Kong and Chinese-Han

You may not qualify if:

  • Non-Chinese or non-local case and control subjects;
  • Either of the parents are non-Chinese;
  • Case and control subjects who do not speak or understand Cantonese or Chinese;
  • Age \<40 for control subjects;
  • Subjects who are pregnant;
  • Unable to provide signed informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Medicine

Central, Hong Kong

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood sample in K2EDTA and SST tubes and/or buccal swab

MeSH Terms

Conditions

Dermatitis, AtopicSkin Diseases, GeneticEczema

Condition Hierarchy (Ancestors)

Genetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Mandy Chan, MBBS

    The University of Hong Kong

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Assistant Professor

Study Record Dates

First Submitted

October 29, 2019

First Posted

November 7, 2019

Study Start

July 12, 2019

Primary Completion

December 31, 2021

Study Completion

June 30, 2022

Last Updated

May 5, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

No plan to share individual participant data

Locations